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ABSTRACT 
Achieving efficient β-cell regeneration is a major goal 
of diabetes research. Previously, we found that a 
combination of β-cell ablation and pancreatic duct 
ligation led to β-cell regeneration by direct conversion 
from α-cells. Here, we studied the effect of surgical 
reversal of the duct ligation, finding that there was a 
wave of β-cell replication following reversal. The 
combination of β-cell neogenesis prior to reversal of the 
duct ligation and β-cell replication following reversal 
resulted in efficient β-cell regeneration and eventual 
recovery of function. This provides an important proof 
of principle that efficient β-cell regeneration is possible, 
even from a starting point of profound β-cell ablation. 
This has important implications for efforts to promote 
β-cell regeneration . 
 
 
 
INTRODUCTION 
 
Because decreased β-cell number is a central 
feature of both type I and type II diabetes, 
inducing β-cell regeneration has been a focus 
of efforts to develop a definitive treatment for 
diabetes. A prevalent approach to studying β-
cell regeneration is to induce damage to the 
pancreas and then dissect the process by which 
regeneration occurs. Common damage models 
have included partial pancreatectomy [1, 2], 
pancreatic duct ligation (PDL [3-5]), and 
chemical β-cell ablation [4, 6]. 
 
An issue of considerable importance that has 
been inadequately addressed is whether β-cell 
regeneration can fully reconstitute a normal 
number of β-cells, particularly starting from a 
condition of severe β-cell deficiency as occurs 
in type I diabetes. In large part, efforts to 
address that question have been confounded by 
the considerable controversy that exists about 
the mechanism and the extent to which β-cell 
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regeneration occurs in the various damage 
models [1, 4, 5, 7, 8]. In fact, most damage 
models, including PDL and partial 
pancreatectomy, do not involve β-cell ablation, 
and in most studies in which β-cell ablation has 
been a feature, it has not been efficient, making 
it impossible to determine the maximum extent 
of β-cell regeneration from the very low 
starting point that exists in some cases, 
particularly type I diabetes. Efficient β-cell 
ablation using a transgenic mouse in which the 
diphtheria toxin receptor was expressed under 
the control of the insulin promoter has been 
studied, with the finding that β-cell neogenesis 
from α-cells occurred, but only partial β-cell 
reconstitution was achieved and reversion to 
normoglycemia took 5-10 months [9]. 
 
Previously, we developed a new model of 
pancreatic damage that combined PDL and 
severe β-cell ablation using high dose alloxan 
[4]. While it is now clear that β-cell neogenesis 
from duct cells or Ngn3-positive intermediates 
does not occur following PDL alone [5, 8], 
when we combined PDL with β-cell ablation, 
β-cell neogenesis from α-cells was rapid and 
efficient. α- and β-cell replication occurred to 
some extent, but neogenesis and replication 
were completely unlinked, consistent with their 
being under distinct regulatory control. 
Because of the severe and continuing injury 
from PDL, it was not possible to maintain the 
mice for a long enough period to study the long 
term outcome. In particular, we could not 
determine the full extent of recovery in the 
number of β-cells or the extent to which the 
increased number of β-cells would translate 
into increased β-cell function. 
 
We hypothesized that reversing the effects of 
the inflammatory milieu in which the neogenic 
β-cells existed following PDL might allow us 
to answer questions about the extent of β-cell 
recovery following PDL plus alloxan. One 
possibility was that β-cell regeneration would 
cease once the damage stimulus of PDL ended. 
Another possibility was that β-cell 
regeneration, whether in terms of β-cell 
number or maturation, would continue. To 
distinguish between those possibilities, we 
surgically reversed the PDL. PDL reversal (Re-
PDL) resulted in rapid normalization of the 
exocrine pancreatic architecture and allowed us 
to follow the mice for a longer period to 
determine the ultimate effect on β-cell number 
and function. 
 
Following Re-PDL, the number of β-cells 
increased enormously. Surprisingly, this was 
due to a wave of β-cell replication. Over a long 
period, newly formed immature β-cells 
acquired characteristics of mature β-cells, 
including the expression of MafA, membrane-
localized GLUT2, and PDX-1. Islet 
architecture, which was severely disrupted 
following PDL plus alloxan, gradually reverted 
to the normal state, with β-cells internal to α-
cells. The combination of β-cell neogenesis 
following PDL plus alloxan in combination 
with the β-cell replication that occurred 
following Re-PDL resulted in a normal number 
of β-cells. We conclude that, at least in young 
mice, β-cell regeneration from a starting point 
of profound β-cell deficiency is sufficiently 
robust to reconstitute a normal number of β-
cells and lead to a major improvement in β-cell 
function. This finding offers encouragement for 
efforts to induce effective and efficient β-cell 
regeneration. 
 
MATERIALS AND METHODS 
 
Animal procedures 
All animal experiments were approved by the 
Institutional Animal Care and Use Committee 
of the Sanford-Burnham Medical Research 
Institute in accordance with national 
regulations. 
 
PDL and PDL Reversal 
Four week old male ICR mice were purchased 
from Harlan Sprague Dawley. All Re-PDL 
procedures were done with ICR mice, in 
contrast with our previous study [4] that used 
Efficient β-cell regeneration 
 
 3
primarily C57BL/6J mice. The choice of ICR 
mice was dictated by the fact that Re-PDL was 
technically difficult and associated with high 
mortality. ICR mice are larger than C57BL/6J 
at the same age (26-30 grams versus 22-25 
grams at 4 weeks of age) and gain body weight 
faster under normal conditions and 
postoperatively. On average, mice lost 
approximately 1/3 of their body weight in the 
postoperative period, making it advantageous 
to use larger mice to start. In terms of the 
surgical procedure, we found that C57BL/6J 
had more connective tissue between the 
abdominal organs than ICR mice, making 
surgery on C57BL/6J more difficult. 
 
Mice underwent PDL plus alloxan treatment as 
previously described [4, 10]. One week 
following PDL plus alloxan, mice with blood 
glucose levels >500mg/dL were divided into 2 
groups: PDL (n=10) and PDL followed one 
week later by Re-PDL (n=26). Six of the 10 
PDL alone mice died within two weeks of 
surgery. Pancreases of sufficient quality for 
analysis were harvested from two mice that 
died or became sick and so were sacrificed per 
the terms of our animal care protocol at 17 and 
19 days following PDL plus alloxan injection- 
analyzed as the PDL alone early group. Two 
PDL alone mice survived for 35 and 52 days 
following PDL and were analyzed as the PDL 
alone late group. 
 
Of the 26 mice that survived for at least one 
week following Re-PDL, 5 had tissue harvested 
between days 15 and 18 following PDL and 
were analyzed as the Re-PDL early group. Six 
Re-PDL mice had tissue harvested at late times 
following PDL and were analyzed as the Re-
PDL late group. One mouse in the Re-PDL 
group exhibited partial recovery of the exocrine 
pancreas and was analyzed separately. The 
pancreases from the remaining mice could not 
be harvested due to degradation. The day of 
sacrifice for the mice in the late groups is 
presented in the figure legends. 
 
Re-PDL was done as follows: After anesthesia 
with ketamine/xylazine, sutures that were used 
to close the skin and abdominal muscles were 
removed and the incision was opened by gently 
stretching skin and abdominal muscle on both 
sides. The pancreas distal to the ligation 
exhibited severe exocrine atrophy, with islets 
being visible surrounded by translucent 
connective tissue and blood vessels. The suture 
used to ligate the duct was removed by gently 
untying the knot. The duct distal to the ligation 
was gently massaged until fluid was observed 
flowing antegrade through the duct. The wound 
was then closed. 
 
To determine which cells replicated following 
PDL or Re-PDL, BrdU (1mg/ml, Sigma-
Aldrich) was administered in the drinking 
water beginning on day 1 after Re-PDL or day 
8 after PDL and continuing for 5-6 weeks. 
Diabetic mice were injected subcutaneously 
once daily with insulin glargine (Sanofi-
Aventis). Insulin doses were adjusted 
depending on blood glucose level. After the 
mice had 4 consecutive blood glucose 
measurements <200mg/dL within one week, an 
intravenous glucose tolerance test (IVGTT) 
was performed to test for β cell function. After 
IVGTT, the mice were sacrificed and the 
pancreas harvested. When the pancreas were 
harvested for histology in the Re-PDL group, 
the section of pancreas distal to the ligation had 
greatly increased in size but still appeared to be 
slightly smaller than prior to PDL. Compared 
with the proximal pancreas, it was whiter in 
color, allowing it to be clearly distinguished 
from the proximal pancreas. Using that 
morphological difference, the pancreas was 
separated into two parts, one proximal and one 
distal to the PDL. 
 
IVGTT 
For IVGTT, the mice were fasted for 12 hours, 
followed by penile vein injection of 0.5 g/kg 
Dextrose (Hospira, Lake Forest, IL). Blood was 
collected via tail vein at 0, 1, 5, 10, 15, 30, 60, 
90,120, 150 and 180 minutes after dextrose 
injection. A small drop of blood was withdrawn 
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from the tail vein and glucose measured using a 
OneTouch UltraMini glucometer. 
 
Histology and Immunochemical staining 
Tissue was fixed in 4% paraformaldehyde 
(Santa Cruz Biotechnology, Inc) for 12 hours at 
40 C, washed in Phosphate buffered saline 
(PBS), followed by overnight incubation at 40C 
in 30% sucrose (Sigma-Aldrich). Samples were 
then embedded in OCT compound and frozen 
at -800C. Cryosections of 5 μm thickness were 
incubated with primary antibody (Table 1) 
overnight at 40C. Secondary antibodies (Table 
1) were added and incubated for 45 minutes. 
Antigen retrieval was used for BrdU and MafA 
staining. Nuclei were visualized by DAPI 
staining (Sigma-Aldrich). 
 
Quantification of β-cell area and number 
All slides were scanned and analyzed using the 
Aperio ScanScope XT system (version 10, 
Aperio Technologies, Vista, California). 
Insulin positive area per section was calculated 
by dividing the area of insulin positive area by 
the pancreas area. The number of insulin 
positive cells was calculated by counting the 
number of DAPI-positive nuclei surrounded by 
insulin positive cytoplasm. The number of 
insulin-BrdU double-positive cells was 
calculated by counting the number of BrdU 
stained nuclei surrounded by an insulin-
positive cytoplasm. 
 
Statistical analysis 
Data are presented as mean±SEM. The 
statistical significance of the differences 
between groups was analyzed by Student’s t-
test. The Kaplan-Meier curve was analyzed by 
log-rank test. 
 
RESULTS 
 
Reversal of PDL led to rapid recovery of the 
exocrine pancreas 
PDL reversal (Re-PDL) was performed by 
untying the suture used to ligate the pancreatic 
duct one week after PDL plus alloxan. While 
PDL led to complete (compare Figure 1 A and 
B) and irreversible (Figure 1D) elimination of 
the exocrine enzyme amylase expression, Re-
PDL led to rapid (Figure 1F) and almost 
complete (Figure 1H) recovery of the exocrine 
pancreas (quantified in Figure 1M). In neither 
PDL nor Re-PDL animals was there any effect 
on the exocrine pancreas proximal to the 
ligation (Figure 1A, E, C, G). 
 
To monitor for cellular replication following 
Re-PDL, BrdU was administered in the 
drinking water beginning one day after reversal 
(or the analogous time for the controls) and 
continuing for 5-6 weeks. Unexpectedly, the 
acinar cells present after Re-PDL were 
composed of a mixture of BrdU-positive and 
BrdU-negative cells. This indicates that many 
acinar cells did not arise by replication of an 
acinar cell precursor, but rather from pre-
existing acinar cells that had lost amylase 
expression. 
 
β−cell neogenesis following PDL and Re-
PDL 
Consistent with our previous study of β-cell 
neogenesis following PDL plus alloxan [4], 
large numbers of cells co-expressing α- and β-
cell markers, most notably glucagon and 
insulin, were found within two to three weeks 
following PDL plus alloxan (yellow cells in 
Figure 2B, F, Suppl. Figure 1). There was 
almost no colocalization of insulin and 
glucagon at later times following PDL or Re-
PDL (Figure 2D, H), indicating that β-cell 
neogenesis occurred in a brief wave. 
 
Also consistent with our previous results, β-cell 
regeneration did not occur proximal to the 
ligation in either PDL or Re-PDL animals 
(Figure 2C, G)(Figure 3 C, G, K, O)(quantified 
in Figure 3R, S). This indicates that the 
stimulus for β-cell neogenesis was local, i.e., 
restricted to the pancreatic tail, the area distal 
to the PDL. This is in contrast to β-cell 
replication following partial pancreatectomy, 
where the effect of partial pancreatectomy on 
β-cell replication was equal throughout the 
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pancreas, regardless of the distance from the 
site of the surgery [1]. 
 
β-cell replication and normalization of β-cell 
area following Re-PDL 
At later times following Re-PDL, there was a 
dramatic increase in the number of β-cells 
compared with PDL (Figure 2H vs. D)(Figure 
3H vs. D, P vs. L, quantified in Q, R). Since 
there was no evidence of continuing β-cell 
neogenesis in the form of cells coexpressing 
multiple hormones, we examined β-cell 
replication as a possibility. Most of the new β-
cells shortly after Re-PDL were negative for 
BrdU (Figure 3N, quantified in S), consistent 
with their having arisen by neogenesis rather 
than by replication of the rare β-cells that 
survived alloxan treatment. However, at late 
times following Re-PDL, there was an 
enormous increase in the number of BrdU-
positive β-cells (Figure 3H, P, quantified in S). 
Thus, an unexpected wave of β-cell replication 
occurred following Re-PDL. 
 
Islet structure and β-cell area returned to 
normal following Re-PDL 
A conspicuous feature of islets immediately 
following β-cell ablation and regeneration is a 
disorganized structure in which the different 
islet cell types are intermingled rather than 
segregated with β-cell internal to the α- and δ-
cells (Figure 4A, B). With the large increase in 
the number of β-cells following Re-PDL and 
the opportunity to follow the animals for a 
prolonged period, it was of interest to 
determine whether the islet structure returned 
to normal. In contrast with the disorganized 
structure early after PDL and Re-PDL, by 10 
weeks following Re-PDL the islet structure had 
begun to normalize (Figure 4C), and essentially 
normal islets were found at later times (Figure 
4D). 
 
To determine the extent to which a 
combination of β-cell neogenesis and β-cell 
replication could reconstitute a normal number 
of β-cells, we measured the insulin-positive 
area as a fraction of the distal or proximal 
pancreatic area on each section. Strikingly, the 
β-cell area following Re-PDL was 
indistinguishable from normal mice that had 
not undergone surgery or β-cell ablation 
(Figure 4E), demonstrating virtually complete 
β-cell regeneration from almost complete 
absence following high dose alloxan. 
 
β-cells gradually matured following Re-PDL 
Previously, we found that β-cells that were 
present following PDL plus alloxan had an 
immature phenotype [4]. This appeared to be 
due to selective survival of a preexisting 
population of immature cells that survive high 
dose alloxan due to the absence of GLUT2, 
which is required for alloxan to enter the cell 
[11]. Similar to our previous results [4], 
insulin-positive cells in the early period 
following PDL or Re-PDL lacked detectable 
levels of GLUT2, MafA, or PDX-1 (Figure 5). 
Following Re-PDL, the β-cells gradually 
matured, acquiring all three of those markers of 
functional β-cells (Figure 5H, P, X). 
 
A mouse in which Re-PDL was only partially 
successful as determined by limited exocrine 
regeneration (Suppl. Figure 2A–C) was 
instructive. It failed to exhibit maturation of the 
surviving β-cells, which remained negative for 
PDX-1 (Suppl. Figure 2D, E), MafA (Suppl. 
Figure 2F, G), and GLUT2 (Suppl. Figure 2H, 
I). β-cell regeneration was restricted to areas 
where acinar regeneration took place (compare 
Suppl. Figure 2B and C, high power view of 
regenerating islets inset), suggesting that the 
pancreatic milieu following PDL is unfavorable 
for β-cell maturation. 
 
Mice with Re-PDL exhibited improved 
glucose homeostasis and survival 
Given the maturation of β-cells as determined 
by the acquisition of GLUT2, MafA, and PDX-
1 in mice that underwent Re-PDL, we 
performed a time course analysis of the blood 
glucose concentration. As we found previously, 
the control PDL plus alloxan mice remained 
severely diabetic (red line in Figure 6A) and 
none survived past day 50 (red line in figure 
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6B). However, the blood glucose concentration 
in mice that underwent Re-PDL began to drop 
immediately following Re-PDL (black line in 
Figure 6A). Mice that underwent Re-PDL had a 
highly statistically significant survival 
advantage (Figure 6B). The mouse that had 
incomplete Re-PDL (Suppl. Figure 2) survived 
until day 150, but did not revert to 
normoglycemia (green line in Figure 6A). No 
long term surviving mice were found in which 
acinar cell recovery did not occur. To 
determine the extent to which β-cell function 
was completely restored, mice were subjected 
to IVGTT. Glucose tolerance was substantially 
improved but not normal (Figure 6C). 
 
DISCUSSION 
 
The principal finding of this study is that a 
combination of neogenesis and replication is 
capable of completely reconstituting a normal 
number of β-cells from a baseline in which 
there were very few preexisting β-cells. This is 
an important proof of principle that β-cell 
regeneration can be an effective therapy for 
diabetes, potentially even in settings where the 
number of β-cells is close to or at zero [12]. 
 
There are relatively few studies of β-cell 
regeneration in animals that underwent severe 
β-cell ablation [9] and none that we are aware 
of achieved complete β-cell reconstitution. 
Previously studied damage models induced β-
cell neogenesis or β-cell replication, but not 
both. In our model, regeneration appears to 
have occurred in two distinct phases; an initial 
burst of β-cell neogenesis from α-cells 
followed by a wave of β-cell proliferation 
following Re-PDL. The initial burst of β−cell 
neogenesis in response to PDL plus alloxan 
recapitulated our previous study [4], but the 
increased replication of islet endocrine cells 
following Re-PDL was surprising. 
The initial impetus for trying to reverse PDL 
was to determine whether that would lead to a 
return to normoglycemia, and if so in what time 
frame. A previous study of severe β-cell 
ablation found that return to normoglycemia 
took 5-10 months, but it was unclear whether 
that was because continuing regeneration was 
required or because maturation was slow. 
Following Re-PDL, the blood glucose 
concentration began to drop immediately but 
slowly, along with the acquisition of markers of 
mature β-cells. Because of the wave of β-cell 
replication, we could not determine the extent 
to which maturation versus replication 
accounted for the return to normoglycemia. 
 
In summary, beginning from a starting point of 
profound β-cell ablation, and in which the few 
surviving β-cells were immature, we have 
succeeded in achieving complete restoration of 
β-cell number and islet morphology and good 
restoration of β-cell function. This finding is 
encouraging and should provide further 
impetus for efforts to induce β-cell neogenesis 
and replication with pharmacologically relevant 
approaches that can be clinically translated. 
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Figure 1. Reversal of PDL led to rapid recovery of the exocrine pancreas. Pancreases from mice that 
underwent PDL or PDL followed by reversal were immunostained for amylase (red) to visualize the 
acinar cells, and BrdU (green) to detect cells that had replicated. BrdU was administered continuously 
in the drinking water for 5-6weeks beginning one day after Re-PDL or the analogous time in the 
controls. Re-PDL was done one week following PDL. (A-H) Following PDL, there was complete loss 
of exocrine tissue distal to the ligation (loss of amylase staining in B) compared with proximal to the 
ligation (normal amylase staining in A) and no evidence of recovery at later times (D). Following Re-
PDL, there was rapid recovery of the acinar tissue (F, time course in I-L) and this was maintained at 
late points (H)(quantification in M of the area of longitudinal sections through the entire pancreas). 
Recovery was associated with an increase in replication (BrdU staining in F, H). Re-PDL early, n=5. 
Re-PDL late, n=7. PDL early, n=2. PDL late, n=2. Mice were sacrificed at days 35 (C, D) and 171(G, 
H) following PDL. Scale bar=100μm. 
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Figure 2. β-cell neogenesis and recovery of islet structure following Re-PDL. Shortly after PDL plus 
alloxan, there were few surviving β-cells proximal to the PDL (A, E) and this did not change at late 
times (C, G). There were no cells coexpressing insulin and glucagon. Note that yellow dots in A are 
autofluorescence. Distal to the PDL, insulin-glucagon co-positive cells were commonly found early 
(yellow cells in B, F), but were rare at late times following PDL (D, H). Re-PDL early, n=5. Re-PDL 
late, n=7. PDL early, n=2. PDL late, n=2. Mice were sacrificed at days 50 (C), 35 (D), and 171(G, H) 
following PDL. Scale bar=100μm. 
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Figure 3. β-cell replication and number following alloxan plus PDL and Re-PDL. Following PDL, 
there was a small amount of replication in the exocrine pancreas and in the few remaining β-cells (A–
D, low power and I-L, high power). Following Re-PDL, there was a large increase in replication in the 
exocrine pancreas distal but not proximal to the ligation (E-F, low power and M-P, high power). 
Notable particularly at later times following Re-PDL was a large increase in the number of replicating 
β-cells (compare H, P with D, L, quantified in S). This led to an increase in the number of insulin 
positive cells as measured by the number of insulin-positive cells (R) and the β-cell area (S). Note that 
the measurements in Q-S were made per pancreas section, each of which encompassed a 5μM 
longitudinal slice through the entire organ. This was done to control for the effect of PDL, which 
causes a dramatic drop in the pancreas area due to exocrine involution, but should have no effect on 
the absolute β-cell area on each section. Re-PDL early, n=5. Re-PDL late, n=7. PDL early, n=2. PDL 
late, n=2. Mice were sacrificed at days 35 (C, D, K, L) and 171(G, H, O, P) following PDL. Scale bar= 
100μm . 
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Figure 4. Islet structure and β-cell area returned to normal following Re-PDL. At the time of Re-PDL, 
one week after PDL, the islet structure was highly disorganized with a random mixture of α-, β-, and 
δ-cells (A). There was a gradual increase in the number of β-cells and a gradual normalization of the 
islet structure from weeks 2 (B), to 10 (C) to 30 (D). At late times following Re-PDL, the islet 
structure and area in the tail of the pancreas distal to the PDL was indistinguishable from normal (D, 
quantified in E). Note that the exocrine recovery at late times after Re-PDL allowed the use of 
pancreatic area rather than pancreas section for comparison of the β-cell area in the normal pancreas 
compared with the distal pancreas at later times following Re-PDL. Normal, n=4. Re-PDL, n=7. Scale 
bar= 100μm . 
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Figure 5. β-cell maturation following Re-PDL. Following PDL, the surviving β-cells (red) did not 
express GLUT2 (green) (A–D). GLUT2 was present late (G, H) but not early (E, F) following Re-
PDL. Islet morphology was normal late following Re-PDL (H). Similar to GLUT2, MafA (green) was 
not expressed either early or late following PDL (I-L), but did become expressed in β-cells at late 
times following Re-PDL (arrows in P). Similar to GLUT2 and MafA, PDX1 (green) was not expressed 
either early or late following PDL (Q-T). PDX1 became expressed in β-cells at late times following 
Re-PDL (X). Re-PDL early, n=5. Re-PDL late, n=7. PDL early, n=2. PDL late, n=2. Mice were 
sacrificed at days 50 (C), 35 (D, K, L, S, T) and 218 (G), 210 (H) and 171 (O, P, W, X) following 
PDL. Scale bar=100μm. 
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Figure 6. Glucose tolerance and survival following PDL and Re-PDL. Following PDL plus alloxan, 
the blood glucose concentration was greater than 500 mg/dL in all animals (A). The blood glucose 
began to drop immediately, but slowly, following Re-PDL (black line, n=25), except in one animal 
(green line) in which Re-PDL failed as determined by lack of exocrine recovery (Suppl. Figure 2). 
Control animals that did not undergo Re-PDL remained severely diabetic (red line, n=10). Kaplan-
Meier survival plot of mice that underwent PDL with no reversal (red, n=10) or Re-PDL (black, n=26) 
demonstrating improved survival (B). IVGTT of normal (blue, n=5), alloxan-treated diabetic (red, 
n=2) or animals that underwent Re-PDL (black, n=3). IVGTT was done on animals that had reverted 
to normoglycemia and was performed 3-5 days prior to sacrifice (C). 
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Table 1. Antibodies utilized in this study.  
Antibody                                     Supplier                     Dilution 
Amylase (Rabbit)                      Santa Cruz           1:400 
Amylase (Goat)                            Santa Cruz                                1:400 
BrdU (Mouse)                              GE Health    1:400 
Glucagon (Mouse, K79bB10)       Sigma                   1:400 
GLUT2 (Goat)                      Santa Cruz    1:400 
MafA (Rabbit)                                Bethyl       1:100 
Insulin (Guinea Pig)                       USBIO                    1:400 
Insulin (Rabbit, H-86)                    Santa Cruz       1:200 
Pdx-1 (Goat)                                  Abcam          1:1500 
Somatostatin (Goat, D-20)            Santa Cruz    1:200 
Somatostatin (Rabbit)                 Santa Cruz                      1:200 
Alexa 488                               Invitrogen                                1:400 
Rodamin Red                        Jackson Immuno Research      1:400 
Daylight DY                           Jackson Immuno Research       1:400 
 
 
 
